Objectives: This study describes therapeutic drug monitoring (TDM) of posaconazole suspension and modified release (MR) tablets in lung transplant (LTx) recipients and evaluates factors that may affect posaconazole trough plasma concentration (C min ).
Introduction
Posaconazole is a broad-spectrum antifungal with in vitro activity against various fungi including the mucormycetes. Its safety and efficacy in patients with haematological malignancies has been extensively reported. [1] [2] [3] Recent studies have suggested that posaconazole suspension in lung transplant (LTx) recipients may potentially be effective as a pre-emptive therapy. 4, 5 Owing to variability in trough plasma concentration (C min ), a number of international consensus guidelines have recommended therapeutic drug monitoring (TDM) to be performed in patients receiving posaconazole suspension. [6] [7] [8] These recommendations, however, were mostly extrapolated from observations in the haematology setting. Although variability in C min following administration of posaconazole suspension in LTx patients has recently been reported, 4, 9 factors that could contribute to such variability remain to be fully elucidated. Additionally, posaconazole suspension may remain an important alternative in patients with swallowing difficulties or in countries where the modified release (MR) tablet is unavailable.
Currently, little is known about the role of TDM following administration of posaconazole MR tablets in LTx recipients. Whilst posaconazole MR tablets offer the benefits of improved gastrointestinal V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. absorption and bioavailability, 10 these benefits have only been documented in patients with haematological malignancies 1, 11 or in healthy individuals. 12 Therefore, this study aims to describe posaconazole C min in LTx recipients receiving posaconazole suspension and/or MR tablets and explores factors influencing posaconazole C min in this patient cohort.
Methods

Study design and participants
This was a retrospective observational study evaluating posaconazole C min in LTx recipients at The Alfred Hospital, Melbourne, Australia. At our institution, a triple immunosuppressant therapy, consisting of tacrolimus, azathioprine or mycophenolate mofetil and prednisolone, is prescribed to all patients post-LTx. 13 An antifungal is generally prescribed pre-emptively following isolation of fungi from respiratory specimens, including bronchoalveolar lavage and/or sputum, or empirically based on the presence of clinical/radiological signs and symptoms. 4, 13 Although voriconazole remains the first-line antifungal at The Alfred, it is replaced by posaconazole when: (i) patients are intolerant of voriconazole; (ii) voriconazole C min remains sub-therapeutic despite two increases in voriconazole dose; (iii) pre-emptive therapy is indicated against fungal colonization caused by organisms with limited voriconazole susceptibility; or (iv) there is a history of squamous cell carcinoma. The usual starting dose of posaconazole suspension or MR tablets was 400 mg twice daily with food or 300 mg daily without regard to food. Patients were counselled to take posaconazole suspension with or immediately after food and not to crush/chew posaconazole MR tablets. Additionally, patients were educated on the importance of taking their medication strictly as prescribed and were encouraged to discuss any concern with the treating doctors, pharmacists and nurses. Following Australian regulatory approval, posaconazole MR tablets have largely replaced the suspension at The Alfred since September 2015.
From January 2009 to December 2016, the LTx database and pharmacy dispensing records were searched to identify study participants. LTx recipients aged 18 years or older who received posaconazole suspension and/or MR tablets and had posaconazole C min measured from 1 January 2014 to 31 December 2016 were included in the study.
Ethics
This study was approved by the Human Research Ethics Committee of The Alfred Hospital (approval number: 82/15) and Monash University (CF15/681-2015000313). The requirement for informed consent was waived by both ethics committees.
Clinical data collection
Data were extracted from patient medical records and laboratory reports. These included demographic information, indications for LTx, BMI, details of posaconazole therapy (formulation, dosing regimen, indications, C min and monitoring frequency, and documented adverse events), concomitant medications and episodes of hospitalization, ICU stay, enteral feeding, diarrhoea, nausea/vomiting and gastroparesis during posaconazole use. Gastroparesis was confirmed by gastric emptying scintigraphy. In the absence of a documented event, administration of anti-diarrhoeal or anti-nausea medication was used as a surrogate for diarrhoea or nausea/ vomiting, respectively. Adverse events were based on documentation in the medical records as recorded by treating doctors, nurses and pharmacists. Hepatotoxicity was defined as an increase in ALT or total bilirubin of .3 or .1.5 times the upper limit of normal, respectively. 14 Definitions of fungal infection and colonization were adapted from the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements on definitions of infections in cardiothoracic transplant recipients. 15 Colonization was defined as isolation of fungal organisms from the respiratory specimens in the absence of clinical and/or radiological signs/symptoms. Presumed infection was considered in patients with clinical and/or radiological signs/symptoms of infection without histopathological evidence. Proven infection required observation of fungal elements in the tissue or isolation of a fungal organism from a sterile site.
TDM
Throughout the course of posaconazole, TDM and dose adjustments were routinely performed during hospital stays and outpatient clinic visits to ensure therapeutic C min was achieved. To represent C min , blood samples were taken prior to administration of posaconazole in the inpatient setting. When measured in the outpatient clinic, patients were instructed to take posaconazole after the blood test. An in-house assay (ultra-performance LC-tandem MS, Waters Acquity system), validated by the National Association of Testing Authorities Australia, was used to measure posaconazole C min . A C min of at least 0.7 mg/L was considered therapeutic. 7 
Statistical analysis
Data analysis was conducted using Stata 14.0 software (Stata Corp, College Station, TX, USA). Patient characteristics were summarized using descriptive statistics. When appropriate, the Wilcoxon-Mann-Whitney/Kruskal-Wallis test or Fisher's exact/v 2 test was used to assess the difference between continuous or categorical variables, respectively. To adjust for steady state, only posaconazole C min measured at least 5 days after dosing were included in the analysis. 12, 16 Posaconazole C min resulting from suspected non-adherence, as recorded by treating clinicians, were excluded. Multilevel linear regression (with a random effect for patient accounting for correlation amongst repeated measurements of the same individuals) was used to determine and evaluate clinical factors that may potentially influence posaconazole C min (dependent variable). Natural logarithmic transformation of posaconazole C min was performed to improve normality and interpretability of the dependent variable. Coefficients from the regression model were exponentiated and interpreted as proportional (percent) changes in the geometric mean of C min , in which the geometric mean is a measure of central tendency that is usually similar in value to the median. A P value of 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 125 patients were included in the study; 47 received posaconazole suspension, whilst the remaining 78 received posaconazole MR tablets. Proton pump inhibitor (PPI) was concomitantly administered for the treatment/prophylaxis of gastro-oesophageal reflux disease in most patients receiving posaconazole suspension [43/47 (91%)] or MR tablets [70/78 (90%)]. Demographic information and indications for LTx and posaconazole are presented in Table 1 . 
Posaconazole MR tablets
The 78 patients receiving posaconazole MR tablets had a total of 617 posaconazole C min measurements. In 72/78 (92%) patients, 300 mg daily was prescribed as a starting dose. The median (IQR) posaconazole C min , which was measured during concurrent PPI administration at a median (IQR) of 7 (6-10) days following the initial 300 mg daily dose was 1.65 (0.97-2.13) mg/L. Although switching from posaconazole suspension to MR tablets afforded an increase in C min (Figure 3 ), variability in C min remained and dose adjustments were required in 57/78 (73%) patients to maintain a C min between 0.7 and 2 mg/L (Figure 4 ). Inter-and intra-patient variability in C min was reported in patients receiving 200 and 300 mg daily of posaconazole tablets ( Figure 5 ).
Posaconazole C min and adverse events
Adverse events were documented in two patients receiving posaconazole suspension. Posaconazole suspension was ceased in one patient following agitation that developed 5 days post-initiation of therapy, and in the other owing to concern about abnormal liver functions after 6 months of continuous therapy. Although the ALT and total bilirubin of the latter patient were not substantially higher than the upper limits of normal (66 and 21 U/L, respectively), alkaline phosphatase of 1056 U/L prompted the cessation of posaconazole suspension. Posaconazole C min for these two patients at the time when the adverse events were documented was 0.35 and 1.39 mg/L, respectively. Cessation of posaconazole led to resolution of the agitation and gradual improvement of the liver functions, respectively.
Of the patients receiving posaconazole MR tablets, three reported sudden onset of fatigue, tremor, lethargy, sweating, nausea/vomiting and weight loss. Posaconazole C min following a daily dose of 300 mg, in these patients when the symptoms first developed, were 9.6, 6.2 and 2.33 mg/L. Complete resolution of the symptoms was achieved following dose and C min reduction to ,2 mg/L. No episode of clinically significant hepatotoxicity was observed.
Factors related to posaconazole C min
Multilevel linear regression analysis found that in patients receiving posaconazole suspension, administration of enteral feeding was associated with 30% reduction in C min (Table 2) . Conversely, male gender, treatment in an outpatient setting or gastroparesis was associated with a 42%, 15% or 70% increase in the C min , respectively. Whereas daily doses larger than 800 mg did not appear to consistently result in higher C min , a dose of 1600 mg daily was associated with a 45% increase in C min (Table 2) .
For posaconazole MR tablets, multilevel regression analysis suggested that posaconazole C min was 48% lower in cystic fibrosis patients, whereas administration of posaconazole MR tablets in an outpatient setting or the presence of underlying gastroparesis was associated with a 25% or 30% increase in posaconazole C min , respectively (Table 3) . In contrast to posaconazole suspension, a clear dose-response relationship was observed in patients receiving posaconazole MR tablets (Table 3) . 
Discussion
To the best of our knowledge, this is the first and largest study exploring the TDM of posaconazole MR tablets in the LTx setting to date. The data suggested that variability in C min remained despite the administration of posaconazole MR tablets. Importantly, clinical factors that may potentially affect the posaconazole C min in LTx patients taking posaconazole MR tablets were identified for the first time.
Our study suggested that, when taking patient factors into account, escalating the posaconazole suspension dose to beyond 800 mg daily did not appear to result in consistent increases in C min . However, we noted that a dose of 1600 mg daily of posaconazole suspension in the present study resulted in significantly TDM of posaconazole in lung transplantation JAC higher C min , consistent with the work of Shields et al. 9 In our study, 1600 mg daily of posaconazole was administered in either two or four divided doses. The median (IQR) of posaconazole C min following twice daily or four times daily administration was not statistically different: 0.97 (0.89-1.28) versus 1.03 (0.56-1.75), P " 0.76. Although the reasons behind this observation were unknown, no adverse events were documented following administration of 1600 mg daily of posaconazole suspension in our study. However, episodes of liver toxicity and gastrointestinal adverse events following 1600 mg daily of posaconazole suspension have been reported by others. 9 Therefore, the use of posaconazole suspension beyond the manufacturer's recommended dose to boost C min requires careful consideration.
Compared with the suspension, posaconazole MR tablets were associated with higher C min in our study, consistent with findings from the haematology setting. 2, 11 Owing to pharmacokinetic characteristics, 1 the median initial C min following 300 mg daily of posaconazole MR tablets was .1 mg/L. The MR tablets, thus, may offer an advantage over the suspension when rapid achievement of a high posaconazole C min is required. Given the small number of patients or events, and different follow-up periods, we were unable to determine the clinical effectiveness of posaconazole MR tablets or the association between posaconazole C min and clinical response. Nevertheless, the efficacy of posaconazole suspension in LTx recipients has been reported. 4, 5 In the present study, variability in posaconazole C min remained despite administration of the MR tablet formulation. Our experience suggested that administration of 300 mg daily of posaconazole MR tablets resulted in C min .1 mg/L in more than 75% of patients. Similarly, Stelzer et al. 17 also demonstrated a significant C min variability amongst LTx recipients receiving 300 mg daily of posaconazole MR tablets (C min ranged from 0.4 to 8.7 mg/L). At our institution, dose reduction/increment, by 100 mg daily, was routinely undertaken to maintain a C min between 0.7 and 2 mg/L. Interestingly, in this study, the use of 100 mg daily of posaconazole MR tablets was sufficient to afford therapeutic C min in some patients, although a daily dose of up to 600 mg was required in others. Hence, it would be useful to identify patients who are prone to develop sub-or supra-therapeutic C min prior to commencement of posaconazole, so that an appropriate dose can be instituted.
Notably, factors contributing to C min variability amongst patients with haematological malignancies and LTx recipients are not entirely identical, potentially owing to the differences between these two groups of patients (e.g. physiological variables). Dolton et al. 18 had previously reported concurrent ranitidine or metoclopramide therapy, underlying diarrhoea or mucositis as predictors for lower C min in patients with underlying haematological malignancies who received posaconazole suspension. Similarly, in their cohort of haematological malignancy patients and recipients of haematopoietic stem cell transplant with graftversus-host disease who received posaconazole MR tablets, Tang et al. 19 reported that sub-therapeutic C min was more likely to occur during episodes of diarrhoea or concurrent proton pump inhibitor therapy. We, however, did not observe such associations in our LTx patient cohort, regardless of the posaconazole formulation taken.
Although diarrhoea or nausea/vomiting in the current study was associated with lower posaconazole C min in the univariate analysis, multilevel linear regression analysis did not reveal any statistically significant association. Whilst these gastrointestinal disturbances following LTx are common, they are generally mild in nature. 20 Thus, their impact on posaconazole absorption is potentially minimal. When enteral feedings were administered to compensate for reduced oral intake in LTx patients, significantly lower C min was observed in patients receiving posaconazole suspension. In contrast, such association was not observed in those receiving posaconazole MR tablets, supporting the previous finding that their absorption is not affected by food. 10 In contrast, patients with gastroparesis, which is a common complication following LTx, 21 were found to have a higher C min in the current study regardless of the TDM of posaconazole in lung transplantation The bold formatting signifies statistically significant covariates.
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posaconazole formulation administered. Delay in gastrointestinal transit may have increased posaconazole absorption from the gut. The current study found a significantly lower median posaconazole C min in patients with cystic fibrosis. However, when adjusted for the other variables in the multilevel linear regression model, this difference was no longer significant in patients taking posaconazole suspension. In those taking posaconazole MR tablets, however, the relationship between underlying cystic fibrosis and posaconazole C min remained. Inherent to reduced gastrointestinal absorption and increased drug clearance, patients with cystic fibrosis often experience altered dispositions of many drugs. 22 A recent study demonstrated significantly lower posaconazole exposure in LTx recipients with cystic fibrosis who received posaconazole suspension. 23 Although the pharmacokinetics of posaconazole MR tablets in this patient population has yet to be evaluated, posaconazole C min should be closely monitored in these patients until further data are available.
Given that PPI was concomitantly administered in 90% of our patients, we were unable to evaluate the impact of PPI on posaconazole C min in the present study. A previous study has demonstrated that concomitant administration of posaconazole suspension with PPI in LTx recipients resulted in significantly lower posaconazole C min , 9 although the authors only adjusted for oral administration and concomitant H 2 antagonist administration in their model. Although no study has quantified the effect of concomitant PPI therapy and posaconazole MR tablets in the LTx setting, Stelzer et al. 17 did demonstrate a lower posaconazole C min in patients receiving concomitant 80 mg daily of pantoprazole compared with those receiving 40 mg daily. Given the negligible impact of gastric pH on posaconazole MR tablet absorption, the impact of PPI would likely be minimal, as previously reported in healthy individuals 24 and patients with haematological malignancies. 2 In the current study, despite having controlled for concomitant medications and other variables, both inter-and intra-patient variability in posaconazole C min remained, consistent with findings from other studies. 17, 25 We were, however, unable to rule out the possibility of other important patient factors that could potentially influence posaconazole C min . Genetic polymorphisms of P-glycoprotein (P-gp) or UDP-glucuronosyltransferases (UGT), for example, have been reported to affect the plasma concentration of certain drugs. 26, 27 Although Sansone-Parsons et al. 28 demonstrated a lack of association between P-gp polymorphism and posaconazole clearance, the impact of UGT polymorphism on the metabolism of posaconazole is yet to be reported. Further investigation is required.
The present study is the first to report symptoms of lethargy, sweating, weight loss and fatigue in three patients with posaconazole C min .2 mg/L. Although unable to be definitively attributed to posaconazole toxicity, these symptoms completely resolved when posaconazole C min was reduced to ,2 mg/L. Of interest, Parkes et al. 29 recently reported visual hallucinations and cognitive impairment in a patient receiving posaconazole tablets. The posaconazole C min in this patient, when the symptoms developed, was 10.10 mg/L. Posaconazole tablets were subsequently withheld and improvement in symptoms was observed following reduction in posaconazole C min . Consistent with findings from previous studies, 11, 30 no episodes of hepatotoxicity were documented in the 42 patients with C min .2 mg/L in our study. Nevertheless, it is worth noting that a recent study of patients with haematological malignancies reported episodes of hyperbilirubinaemia, although not attributed to posaconazole, in patients with C min .1.83 mg/L. 3 Given that the relationship between posaconazole C min and adverse events has yet to be established, 1, 11 further surveillance is warranted.
In conclusion, this study has provided clinically important insights into the TDM of posaconazole in LTx patients receiving posaconazole suspension and/or MR tablets. Non-specific signs or symptoms of adverse effects were documented in some patients with C min .2 mg/L, although no episodes of liver toxicity were observed. Further study should aim to delineate the patient factors relating to posaconazole C min variability in the LTx setting, which we were unable to investigate. Owing to the inter-and intrapatient variability, findings from the current study support the need for regular TDM in LTx patients prescribed posaconazole suspension and/or MR tablets.
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